Table 3.
Cervical Spondylosis | ||||||||
---|---|---|---|---|---|---|---|---|
No | Yes | |||||||
Event | PY | Rate # | Event | PY | Rate # | Crude HR (95% CI) | Adjusted HR § (95% CI) | |
Sex | ||||||||
Women | 293 | 81,923 | 3.58 | 841 | 76,664 | 11.0 | 3.04 (2.66, 3.48) *** | 3.38 (2.95, 3.86) *** |
Men | 244 | 55,477 | 4.40 | 600 | 53,605 | 11.2 | 2.54 (2.19, 2.94) *** | 2.84 (2.44, 3.30) *** |
Stratify age | ||||||||
≤49 | 99 | 51,648 | 1.92 | 341 | 56,550 | 6.03 | 3.14 (2.51, 3.93) *** | 3.61 (2.88, 4.53) *** |
50–64 | 213 | 54,428 | 3.91 | 574 | 48,091 | 11.9 | 3.03 (2.59, 3.55) *** | 3.48 (2.97, 4.08) *** |
65+ | 225 | 31,325 | 7.18 | 526 | 25,628 | 20.5 | 2.81 (2.40, 3.29) *** | 2.77 (2.37, 3.25) *** |
Occupation | ||||||||
White collar | 252 | 68,498 | 3.68 | 635 | 66,957 | 9.48 | 2.57 (2.22, 2.98) *** | 2.98 (2.57, 3.45) *** |
Blue collar | 209 | 50,511 | 4.14 | 552 | 46,298 | 11.9 | 2.85 (2.43, 3.35) *** | 2.98 (2.57, 3.45) *** |
Others & | 76 | 18,392 | 4.13 | 254 | 17,015 | 14.9 | 3.59 (2.78, 4.63) *** | 3.63 (2.80, 4.70) *** |
Urbanization level † | ||||||||
1 (highest) | 176 | 44,789 | 3.93 | 439 | 43,227 | 10.2 | 2.57 (2.16, 3.06) *** | 2.91 (2.44, 3.47) *** |
2 | 166 | 41,892 | 3.96 | 418 | 39,867 | 10.5 | 2.64 (2.20, 3.16) *** | 2.95 (2.46, 3.53) *** |
3 | 66 | 21,780 | 3.03 | 247 | 20,815 | 11.9 | 3.89 (2.96, 5.10) *** | 4.23 (3.22, 5.56) *** |
4 (lowest) | 129 | 28,940 | 4.46 | 337 | 26,360 | 12.8 | 2.84 (2.32, 3.48) *** | 3.01 (2.45, 3.69) *** |
Comorbidity ‡ | ||||||||
No | 115 | 60,271 | 1.91 | 344 | 59,401 | 5.79 | 3.04 (2.46, 3.75) *** | 3.66 (2.96, 4.53) *** |
Yes | 422 | 77,130 | 5.47 | 1097 | 70,868 | 15.5 | 2.80 (2.50, 3.13) *** | 2.89 (2.58, 3.23) *** |
Rate #, incidence rate, per 1000 person-years; Crude HR, relative hazard ratio; Adjusted HR §: mutually adjusted for age, sex, frequency of medical visits/per year, occupation, urbanization level, comorbidity of diabetes, hypertension, hyperlipidemia, CAD, stroke, CKD or ESRD, COPD, cancer, CHF, and medications of NSAID, beta blocker, propranolol, carvedilol, and bisoprolol by using Cox proportional hazards regression; Comorbidity ‡: Patients with any one of the comorbidities diabetes, hypertension, hyperlipidemia, CAD, stroke, CKD or ESRD, COPD, cancer, CHF, sleep apnea were classified as the comorbidity group. † The urbanization level was categorized by the population density of the residential area into 4 levels, with level 1 as the most urbanized and level 4 as the least urbanized. & Other occupation categories included those who were primarily retired, unemployed, and low-income populations. *** p < 0.001.